Top Markets
Coin of the day
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
Rang in aandelen #13820
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Aandeelprijs
$12.63
Marktkapitalisatie
$458.19M
Verandering (1 dag)
-3.26%
Verandering (1 jaar)
-
Land
US
Handel Evommune, Inc. (EVMN)

Categorie

Dividendrendementgeschiedenis voor Evommune, Inc. (EVMN)
Het dividendrendement (TTM) van Evommune, Inc. (aandelsymbool: EVMN) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Evommune, Inc. (EVMN) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH